Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial

医学 改良兰金量表 血压 优势比 临床终点 冲程(发动机) 随机对照试验 内科学 麻醉 外科 缺血 缺血性中风 机械工程 工程类
作者
Pengfei Yang,Lili Song,Yongwei Zhang,Xiaoxi Zhang,Xiaoying Chen,Yunke Li,Lingli Sun,Yingfeng Wan,Laurent Billot,Qiang Li,Xinwen Ren,Hongjian Shen,Lei Zhang,Zifu Li,Pengfei Xing,Yongxin Zhang,Ping Zhang,Weilong Hua,Fang Shen,Yihan Zhou
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10363): 1585-1596 被引量:161
标识
DOI:10.1016/s0140-6736(22)01882-7
摘要

The optimum systolic blood pressure after endovascular thrombectomy for acute ischaemic stroke is uncertain. We aimed to compare the safety and efficacy of blood pressure lowering treatment according to more intensive versus less intensive treatment targets in patients with elevated blood pressure after reperfusion with endovascular treatment.We conducted an open-label, blinded-endpoint, randomised controlled trial at 44 tertiary-level hospitals in China. Eligible patients (aged ≥18 years) had persistently elevated systolic blood pressure (≥140 mm Hg for >10 min) following successful reperfusion with endovascular thrombectomy for acute ischaemic stroke from any intracranial large-vessel occlusion. Patients were randomly assigned (1:1, by a central, web-based program with a minimisation algorithm) to more intensive treatment (systolic blood pressure target <120 mm Hg) or less intensive treatment (target 140-180 mm Hg) to be achieved within 1 h and sustained for 72 h. The primary efficacy outcome was functional recovery, assessed according to the distribution in scores on the modified Rankin scale (range 0 [no symptoms] to 6 [death]) at 90 days. Analyses were done according to the modified intention-to-treat principle. Efficacy analyses were performed with proportional odds logistic regression with adjustment for treatment allocation as a fixed effect, site as a random effect, and baseline prognostic factors, and included all randomly assigned patients who provided consent and had available data for the primary outcome. The safety analysis included all randomly assigned patients. The treatment effects were expressed as odds ratios (ORs). This trial is registered at ClinicalTrials.gov, NCT04140110, and the Chinese Clinical Trial Registry, 1900027785; recruitment has stopped at all participating centres.Between July 20, 2020, and March 7, 2022, 821 patients were randomly assigned. The trial was stopped after review of the outcome data on June 22, 2022, due to persistent efficacy and safety concerns. 407 participants were assigned to the more intensive treatment group and 409 to the less intensive treatment group, of whom 404 patients in the more intensive treatment group and 406 patients in the less intensive treatment group had primary outcome data available. The likelihood of poor functional outcome was greater in the more intensive treatment group than the less intensive treatment group (common OR 1·37 [95% CI 1·07-1·76]). Compared with the less intensive treatment group, the more intensive treatment group had more early neurological deterioration (common OR 1·53 [95% 1·18-1·97]) and major disability at 90 days (OR 2·07 [95% CI 1·47-2·93]) but there were no significant differences in symptomatic intracerebral haemorrhage. There were no significant differences in serious adverse events or mortality between groups.Intensive control of systolic blood pressure to lower than 120 mm Hg should be avoided to prevent compromising the functional recovery of patients who have received endovascular thrombectomy for acute ischaemic stroke due to intracranial large-vessel occlusion.The Shanghai Hospital Development Center; National Health and Medical Research Council of Australia; Medical Research Futures Fund of Australia; China Stroke Prevention; Shanghai Changhai Hospital, Science and Technology Commission of Shanghai Municipality; Takeda China; Hasten Biopharmaceutic; Genesis Medtech; Penumbra.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_7LMbwn发布了新的文献求助10
刚刚
SciGPT应助饼饼采纳,获得10
刚刚
xinxiangshicheng完成签到 ,获得积分10
1秒前
刘奶奶的牛奶完成签到,获得积分10
1秒前
清爽盼秋完成签到,获得积分10
1秒前
sunyanghu369发布了新的文献求助10
1秒前
2秒前
清蒸可达鸭完成签到,获得积分10
2秒前
锥子完成签到,获得积分10
2秒前
白色的风车发布了新的文献求助200
2秒前
机会啊完成签到,获得积分10
3秒前
123456完成签到,获得积分10
3秒前
迷路的鸽子完成签到,获得积分10
3秒前
苹果王子6699完成签到 ,获得积分10
4秒前
hani完成签到,获得积分10
5秒前
6秒前
激动的xx关注了科研通微信公众号
6秒前
7秒前
柠檬发布了新的文献求助10
8秒前
夸克的诗意完成签到,获得积分10
8秒前
无花果应助yy湫采纳,获得10
8秒前
8秒前
xlj完成签到,获得积分10
8秒前
清欢完成签到,获得积分10
8秒前
土土完成签到,获得积分10
9秒前
滕遥完成签到,获得积分10
9秒前
木木完成签到,获得积分10
10秒前
Oz完成签到,获得积分10
10秒前
迷人耗子精完成签到,获得积分10
10秒前
Shark完成签到,获得积分10
10秒前
Hello应助leo采纳,获得10
11秒前
沙力VAN完成签到,获得积分10
11秒前
gelinhao完成签到,获得积分10
11秒前
正经大善人完成签到,获得积分10
11秒前
CR7应助zhuww采纳,获得20
12秒前
12秒前
13秒前
赖建琛完成签到 ,获得积分10
13秒前
一叶知秋完成签到 ,获得积分10
13秒前
龙傲天完成签到,获得积分10
14秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
A new approach to the extrapolation of accelerated life test data 1000
Coking simulation aids on-stream time 450
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
Novel Preparation of Chitin Nanocrystals by H2SO4 and H3PO4 Hydrolysis Followed by High-Pressure Water Jet Treatments 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4015859
求助须知:如何正确求助?哪些是违规求助? 3555835
关于积分的说明 11318981
捐赠科研通 3288954
什么是DOI,文献DOI怎么找? 1812355
邀请新用户注册赠送积分活动 887882
科研通“疑难数据库(出版商)”最低求助积分说明 812027